(https://liferaftgroup.org)
InarecentarticlefromCancerWorld,(http://www.cancerworld.org/Articles/Issues/64/JanuaryFebruary2015/Cutting
Edge/697/Rightpatientrightdrugwrongdose.html)theauthorexploresthevalueoftherapeuticdrugmonitoringforthose
receivingtargetedtherapies.
Therapeuticdrugmonitoring(TDM)istheclinicalpracticeofmeasuringspecificdrugsatdesignatedintervalstomaintaina
constantconcentrationinthepatientsbloodstream,therebyoptimizingindividualdosageregimens.Itistheclinical
laboratorymeasurementofachemicalparameterthat,withappropriatemedicalinterpretation,willdirectlyinfluencedrug
prescribingprocedures.1
TDMhasbeenrecommendedforimatanibtoimproveefficacy,assesscompliance,andevaluatedrugdruginteractions.2
ItcanalsobeanimportanttoolindiscoveringanyinteractionsGISTmedicationsarehavingwithmedicationsbeingtaken
forotherconditions.
AconcentrationofGleevecinthebloodabove1100ng/mLcorrelateswithbetterclinicaloutcomesaccordingtoGeorge
Demetri,MDoftheDanaFarberCancerInstitute.Moreonthistopiccanbefoundhere
(https://liferaftgroup.org/2013/01/imatinibplasmalevelsrevisited/).
Thearticlesuggeststhatpoorresponsetodrugtreatmentmaybetheresultofastandarddosingapproach,whichdoesnot
requireTDM.
TherehasbeenagroundswellofadvocacyforTDMinEurope,wheretheEuropeanJournalofCancerranaseriesof
positionpapersontheissue,oneinparticularthatmentionsimatinibandsunitinibamongothers.Foralinktothisarticle
clickhere(http://www.ejcancer.com/article/S09598049(14)00598X/abstract).
WhataretheroadblockstomorewidespreadTDM?Havingaccesstofacilitiesthatdothetestingisone.Speedof
turnaroundofresultsisanother.Schedulingpatientscanalsobeachallenge,aswellasthecostinvolved.
RegulatorybarriershavealsocontributedtotheinfrequentorderingofTDM.TheFDAin2010warnedNovartisaboutthe
recommendationfortherapeuticdrugmonitoringforimatinib,citingthattherewasalackofsubstantialevidenceor
substantialclinicalexperiencetosupportacorrelationbetweenpatientoutcomeandplasmalevelsofimatinib.
IncreasedevidenceiswarrantedtohaveTDMinwidespreadclinicaluse.
Plasma/BloodLevelTesting(BLT)isapharmacokineticmethodofdetermininghowmuchimatinib(Gleevec)ispresentina
patientsbloodataspecifictime.Typically,theminimumconcentration(knownastroughlevelorCmin)ismeasuredright
beforetakingthenextdoseofGleevec(ideally2224hoursaftertakingthelastdose).Bymeasuringthisleveldoctorscan
seeifthepatientistakingtheirGleevecasprescribed.
WithvaluableinformationtobeobtainedbytheuseofTDM,morestudiesareclearlycalledfor.Asprogressismadein
adaptingTDMforclinicalpracticeandinadvocacyforitsuse,theLRGwillcontinuetokeepyouposted.
1.TouwDJ,NeefC,ThomsonAH,VinksAA.Costeffectivenessoftherapeuticdrugmonitoring:asystemicreview.Ther
DrugMonit(http://www.ncbi.nlm.nih.gov/pubmed/15665740).200527:1017.
2.Teng,JF,Mabasa,VH,Ensom.Theroleoftherapeuticdrugmonitoringofimatinibinpatientswithchronicmyeloid
leukemiaandmetastaticorunresectablegastrointestinalstromaltumors.TherDrugMonit.
(http://www.ncbi.nlm.nih.gov/pubmed/22215488)2012Feb34(1):8597.
(/#facebook) (/#twitter)
(/#google_plus)
(https://www.addtoany.com/share#url=https%3A%2F%2Flife
therapeuticdrugmonitoringfortargeted
therapies%2F&title=Importance%20of%20Therapeutic%20Drug
CancerWorld(https://liferaftgroup.org/tag/cancerworld/),Dr.GeorgeDemetri(https://liferaftgroup.org/tag/drgeorge
demetri/),Gleevec(https://liferaftgroup.org/tag/gleevec/),PlasmaLevelTesting(https://liferaftgroup.org/tag/plasmalevel
testing/),SaladaxBiomedical(https://liferaftgroup.org/tag/saladaxbiomedical/),TherapeuticDrugMonitoring
(https://liferaftgroup.org/tag/therapeuticdrugmonitoring/)